ACASTI PHARMA INC (ACST)

Company Profile

Acasti Pharma Inc is a CA-based company operating in Pharmaceuticals industry. The company is headquartered in Laval, Quebec. The company went IPO on 2013-03-07. Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The firm is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

Company Info

ACASTI PHARMA INC

3009, Boul. De La Concorde East, Suite 102

Laval QUEBEC H7E 2B5

P: 14506864555

CEO: Jan D'Alvise

Employees: 32

Website: https://www.acasti.com/en